ExThera Medical and Fresenius Medical Care will provide Seraph 100 Microbind affinity filters in Turkey, Finland and Estonia

Martinez, Calif.--(BUSINESS WIRE)--ExThera Medical is the only manufacturer of hemoperfusion filters that are effective in removing pathogens approved for use in patients in Europe, and Fresenius Medical Care It is the world's leading provider of products and services for patients with kidney disease, and announced the expansion of the distribution of ExThera's Seraph 100® Microbind® affinity blood filter in Turkey, Finland and Estonia. Earlier this year, ExThera Medical and Fresenius Medical Care collaborated to distribute Seraph 100® in Europe.

"We are very pleased to expand our partnership with Fresenius to support the provision of Seraph 100 to more patients in the European Union and Turkey. To provide treatment to more countries to help critically ill patients with shock caused by pathogens including COVID-19 , Remains a strong interest and priority of our two companies," said Bob Ward, Chairman and CEO of ExThera Medical.

Since 2019, the treatment device has used the CE mark throughout the continent for the treatment of certain bloodstream infections. In the United States, Seraph 100® is used to treat critically ill COVID-19 patients and recently celebrated the FDA’s research equipment exemption (IDE) approval.

"Seraph 100® is now available to more critically ill patients in the ICU. This is at a critical moment when we are ready to provide available treatment options and help those who struggle with pathogen-related shock (including COVID-19)," said Executive Officer Gunther. Said Gunther Klotz. Vice President of Business Development and Marketing for Fresenius Medical Care Europe, Middle East and Africa.

Seraph 100® is used in intensive care medicine to reduce pathogens in the blood outside the body and can be operated with Fresenius Medical Care acute dialysis machines. Similar to the dialysis process, blood is pumped through a filter to be purified. Seraph is used to reduce pathogens during bloodstream infections as an adjunct to anti-infective treatment.

The device has been proven to effectively bind pathogens such as COVID-19, MRSA and other resistant bacteria. A randomized clinical trial called PURIFY RCT is expected to begin later this year.

ExThera Medical Corporation develops and commercializes extracorporeal blood filtration equipment, including Seraph® 100 Microbind® affinity blood filters, used to remove a wide range of pathogens from patients' blood. Seraph can be used in hospitals, clinics or field hospitals to solve infections caused by battlefield wounds or epidemics. ExThera Medical's in vitro products have shown life-saving capabilities in various critically ill patients with severe infections. With more and more results and health economic evidence from independent clinical research, participation in DARPA-like dialysis therapy programs, and successful clinical applications in the United States and the European Union, the company is ready to provide services to healthcare professionals and patients. Seraph 100® has the CE mark, can be marketed in the European Union, and has received an FDA emergency use authorization (EUA) to treat COVID-19 in the United States.

For more information, please visit the company's website www.exthermedical.com

When the patient's blood flows through the Seraph 100 filter, it passes through beads with receptors that mimic the receptors on human cells that pathogens target when they invade the body. Harmful substances are quickly captured and adsorbed to the surface of the beads, thereby being removed from the bloodstream. Seraph targets the pathogens that cause infections, and it also binds and removes pathogens and harmful substances produced by the body's response to infections. Seraph’s adsorption medium (beads) constitutes a flexible platform that uses immobilized (chemically bonded) heparin because it has good blood compatibility and binds bacteria, viruses, fungi and reportedly cause organ failure during sepsis. The unique capabilities of important sepsis mediators. "Anti-thrombosis" heparin media can be combined with other ExThera proprietary media to customize future Seraph products' ability to treat specific diseases, or to further expand Seraph's capabilities.

For more news reports on Seraph 100, click here.

All information contained in this press release comes from plausible and reliable sources, but has not been independently reviewed. It does not make any guarantee, confirmation or guarantee, nor assume any responsibility or obligation for correctness or completeness. To the extent permitted by relevant laws, we shall not be liable for any direct or indirect losses caused by the release of this press release or its contents. This newsletter includes forward-looking statements about events, trends, and business prospects that may affect our future operating performance and financial condition. Such statements are subject to risks and uncertainties, which may cause our actual results and financial conditions to differ materially. Investment and/or income generated from it may rise or fall. A complete loss is possible. Those holding this press release are required to obtain information about possible legal restrictions and to comply with these restrictions accordingly. We assume no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends or circumstances after the date of this press release.

Lauren Popiel lauren.popiel@resolutepublicaffairs.com 312-768-4773

ExThera expanded the distribution of blood purification and pathogen reduction treatments for sepsis and COVID-19 in Turkey, Finland and Estonia.

Lauren Popiel lauren.popiel@resolutepublicaffairs.com 312-768-4773